AF
KRYS icon

Avanza Fonder’s Krystal Biotech KRYS Stock Holding History

Avanza Fonder’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-996
Closed -$246K – 500
2025
Q4 		$246K Sell
996
-422
-30% -$88.8K 0.01% 415
2025
Q3 		$250K Buy
1,418
+477
+51% +$71.4K 0.01% 378
2025
Q2 		$129K Sell
941
-319
-25% -$46.9K ﹤0.01% 403
2025
Q1 		$228K Buy
1,260
+501
+66% +$84.3K 0.01% 408
2024
Q4 		$119K Buy
+759
New +$135K ﹤0.01% 418

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Avanza Fonder's KRYS Position: Q1 2026 in Review

Avanza Fonder sold out of Krystal Biotech (KRYS) in Q1 2026, closing a stake of 996 shares — an estimated $246K sold.

Avanza Fonder first reported a position in KRYS in Q4 2024 and held it in 5 quarters. The position peaked at $250K in Q3 2025. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • Avanza Fonder reported no remaining Krystal Biotech position as of Q1 2026 after selling out during the quarter.
  • Avanza Fonder sold 996 Krystal Biotech shares in Q1 2026, an estimated $246K.
  • Avanza Fonder first reported a position in Krystal Biotech in Q4 2024 and held it in 5 quarters.
  • Avanza Fonder's Krystal Biotech position peaked at $250K in Q3 2025.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Avanza Fonder's 13F filing for Q1 2026, filed 15 Apr 2026.